Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. HCC typically develops in a cirrhotic liver and the overall survival is poor, primarily because the disease is often diagnosed at an advanced stage, when curable treatment is no longer an option. Ideally, HCC lesions should be detected when they are ≤ 2-3 cm in diameter. The diagnosis of HCC has improved with the introduction of 4-phase contrast enhanced CT and dynamic, contrast enhanced MRI. However, for small lesions, which are potentially curable, the detection rate remains poor. Molecular imaging of specific metabolic pathways may provide new opportunities for early diagnosis of HCC.
Keywords: Liver cancer; Cirrhosis; Contrast-enhanced CT; Dynamic MRI; PET.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Alzheimer Research
Current Aging Science
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents